MAR001
MAR001 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Nov 9, 2026: “ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on MAR001
At a glance
The findings reach people, from one lab or study. 1 lab; 1 trial, none about aging.
“were −39.1 percentage points, −40.5 percentage points, and −45.3 percentage points for the 300-mg, 450-mg, and 900-mg doses, respectively (P<0.001 for all comparisons).”
- 1 lab
- 1 trial, none about aging
- Funder: Marea Therapeutics
- 1 of 1 finding with company ties
- 1 of 1 trial sponsored by its developers
- Human trial1
Studies in people
1 study gave MAR001 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases fasting triglycerides−39.1 percentage points versus placebo; P<0.001 | Randomized trial12 weeks | 235 peopleBothMean 60.4 yearsMidlife adults; adults with elevated triglyceride levels | The New England journal of medicine, Nov 9, 2026 |
What did studies of MAR001 find?
1Studies of MAR001 measured one outcome, fasting triglycerides.
Fasting triglycerides
downin humans1
1 study
Fasting triglycerides
downin humans1
MAR001 decreases fasting triglycerides in humans (adults with elevated triglyceride levels; compared with placebo) (−39.1 percentage points versus placebo; P<0.001).
“were −39.1 percentage points, −40.5 percentage points, and −45.3 percentage points for the 300-mg, 450-mg, and 900-mg doses, respectively (P<0.001 for all comparisons).”
Human trialadults with elevated triglyceride levels; compared with placebomonoclonal antibody300 mg every 4 weeks12 weeks
ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels
The New England journal of medicine
Who is developing MAR001?
1 company: Marea Therapeutics.
- Companies
- Marea TherapeuticsPhase 2hypertriglyceridemia
Trial sponsors
Company1 trialPhase 2316 people